Company profile for Jupiter Neurosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Jupiter Neurosciences, Inc. is a clinical-stage drug platform company focused on treating neuroinflammation. Our mission is to make a significant impact for patients and society through a safe and oral medication for Alzheimer’s disease and for people with rare diseases.We’re a clinical-stage drug platform company focused on treating neuroinflammation. Our mission is making a significant impact for patients and society th...
Jupiter Neurosciences, Inc. is a clinical-stage drug platform company focused on treating neuroinflammation. Our mission is to make a significant impact for patients and society through a safe and oral medication for Alzheimer’s disease and for people with rare diseases.We’re a clinical-stage drug platform company focused on treating neuroinflammation. Our mission is making a significant impact for patients and society through a safe and oral medication for Alzheimer’s disease and for people with rare diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1001 N US Highway 1 Suite 504 Palm Beach Gardens, FL 33477
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

PEGS Boston Summit

PEGS Boston Summit

Not Confirmed

envelop Contact Supplier

PEGS Boston Summit

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/05/27/3301824/0/en/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinson-s-disease.html

GLOBENEWSWIRE
27 May 2026

https://www.globenewswire.com/news-release/2026/05/21/3299804/0/en/jupiter-neurosciences-announces-closing-of-2-0-million-registered-direct-offering.html

GLOBENEWSWIRE
21 May 2026

https://www.globenewswire.com/news-release/2026/05/20/3298378/0/en/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-generation-mdma-therapeutic-from-pharmala-biotech.html

GLOBENEWSWIRE
20 May 2026

https://www.globenewswire.com/news-release/2026/05/20/3298822/0/en/jupiter-neurosciences-announces-pricing-of-2-0-million-registered-direct-offering.html

GLOBENEWSWIRE
20 May 2026

https://www.globenewswire.com/news-release/2026/04/07/3269087/0/en/Jupiter-Neurosciences-Appoints-Kristopher-Fishman-and-Sanjiv-Lal-to-Nugevia-Advisory-Board.html

GLOBENEWSWIRE
07 Apr 2026

https://www.globenewswire.com/news-release/2026/03/31/3265840/0/en/Jupiter-Neurosciences-to-Present-at-Emerging-Growth-Conference-on-April-2.html

GLOBENEWSWIRE
31 Mar 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty